Business
Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology
Ad hoc announcement pursuant to Art. 53 LR EBITDA guidance raised by €4.5M as Cosmo executes on its Vision 2030 strategy; H1 Recurring Revenues from GI Genius™ up 128%, Winlevi® up 23%; Investors Call today at 2 pm CET. ...
About this update from Cosmo Pharmaceuticals Nv
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":1,"height":1,"url":"https://www.newsfilecorp.com/newsinfo/259757/202"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_NQ.yOwmpFY241nQCo0OHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2O2g9MzY7Y2Y9d2VicA--/https://www.newsfilecorp.com/newsinfo/259757/202","width":1,"height":1}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"EBITDA guidance raised by €4.5M as Cosmo executes on its Vision 2030 strategy; H1 Recurring Revenues from GI Genius™ up 128%, Winlevi® up 23%; Investors Call today at 2 pm CET.","length":176,"tagName":"p"},{"type":"text","content":" Dublin, Ireland--(Newsfile Corp. - July 23, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today reported strong half-year results for 2025, underscoring the Company’s strategic execution, commercial momentum, and capital discipline across its key growth platforms.","length":329,"tagName":"p"},{"type":"text","content":"On the back of robust performance in H1 2025, Cosmo has raised its full-year EBITDA guidance by €4.5 million and reconfirmed its total revenue outlook for 2025, while confirming double-digit growth in recurring revenues – driven by its leading products and technologies in MedTech AI and Dermatology.","length":300,"tagName":"p"},{"type":"text","content":"Updated Full-Year 2025 Guidance","length":31,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total Revenues: €102–107 million","length":32,"tagName":"p","attribs":{}}]},{"val":[{"type":"list","items":[{"val":[{"type":"text","content":"~€17 million in project-based revenues","length":38,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"€85–90 million in recurring revenues","length":36,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":74,"olType":false}]},{"val":[{"type":"text","content":"EBITDA: €5.5–7.5 million, raised from previous guidance due to higher-than-expected other income and improved operational efficiencies","length":134,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash, Equivalents & Investments: Expected to remain above €110 million","length":74,"tagName":"p","a...